What is Zacks Research’s Estimate for Pfizer Q1 Earnings?

Pfizer Inc. (NYSE:PFE) – Equities researchers at Zacks Research boosted their Q1 2025 EPS estimates for shares of Pfizer in a note issued to investors on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of $0.63 per share for the quarter, up from their previous estimate of $0.61. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s Q2 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.82 EPS, Q1 2026 earnings at $0.63 EPS and Q2 2026 earnings at $0.58 EPS.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company’s revenue was up 24.7% on a year-over-year basis.

Several other research firms have also recently weighed in on PFE. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 1.3 %

Shares of PFE stock opened at $26.40 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $149.63 billion, a P/E ratio of 18.73, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The stock’s fifty day simple moving average is $26.34 and its 200 day simple moving average is $27.36.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Swedbank AB increased its holdings in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares in the last quarter. Pallas Capital Advisors LLC grew its position in Pfizer by 54.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock valued at $736,000 after purchasing an additional 9,102 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Pfizer by 132.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,361 shares of the biopharmaceutical company’s stock valued at $589,000 after purchasing an additional 11,615 shares in the last quarter. Integrated Advisors Network LLC raised its holdings in Pfizer by 18.3% during the third quarter. Integrated Advisors Network LLC now owns 64,014 shares of the biopharmaceutical company’s stock worth $1,853,000 after buying an additional 9,925 shares during the last quarter. Finally, Fidelis Capital Partners LLC lifted its stake in shares of Pfizer by 5.2% in the third quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 1,267 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. Pfizer’s dividend payout ratio is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.